Ekso Bionics Develops Lightweight Flexible Exoskeleton Technology Expanding Technical & Intellectual Property Leadership
June 05 2017 - 8:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an exoskeleton company,
today announced that it has completed the development of a
lightweight, flexible load carriage exoskeleton prototype named
Artemis.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/87efda25-f992-427d-b9bf-65209981c202
The patent-pending prototype weighs a mere 13 pounds and can
successfully offload up to three-quarters of payload while also
being comfortable to wear. While advancing medical and industrial
exoskeleton technology, the company is exploring applying Artemis
in their product development pipeline.
“Leveraging our extensive core intellectual property provided an
advantage in developing flexible load carriage,” explained Kurt
Amundson, senior director of EksoHealth and EksoLabs. “Our industry
is already actively exploring the benefits of soft exoskeletons.
Recently a team of Harvard engineers published their latest
findings1 which show promise. Ekso engineers will be able to
further explore how to maximize the advantages of soft exoskeletons
thanks to the Artemis prototype.”
The intellectual property from this government-funded project
will be added to Ekso Bionics’ industry-leading IP portfolio of
nearly 200 international patent cases (granted or pending). In late
May, Ekso Bionics was granted a patent for a fail-safe system for
exoskeleton joints, marking the company’s 30th U.S. patent.
To learn more, visit www.eksobionics.com and connect with
us on LinkedIn, Facebook, Twitter, and YouTube. Additional details
regarding Artemis are available in the Ekso Bionics Spring 2017
Company Newsletter:
http://eksobionics.com/wp-content/uploads/2017/05/eksoworks-newsletter-spring-2017-EKSO0063GTREVA.pdf.
About Ekso Bionics®Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) estimates or
projection of financial results, financial condition, capital
expenditures, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not meant
to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
1 Science Robotics, 18 Jan 2017: Vol. 2, Issue 2, eaah4416
The photo is also available at Newscom,
www.newscom.com, and via AP PhotoExpress.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024